


# Claims

What is claimed is:

- 5 1. A compound of formula I:



or a pharmaceutically acceptable salt thereof wherein:

10

A is O,

NH, or

S;

B is

15

C(=O)R<sub>1</sub>,

C(=S)R<sub>1</sub>,

heterocylco,

heteroaryl,

C(=O)-heterocyclo, or


20


C(=O)-heteteroaryl;

D is N when E is C and F is CH when “-----” is a bond, or D is CH when E is N and F is CH<sub>2</sub> when “-----” is absent;

25

P is





, wherein “~~~~” indicates the point of attachment; and

5



is 5-membered heterocyclo or heteroaryl, wherein

“~~~~” indicates points of attachment, and wherein the 5-membered heterocyclo or heteroaryl is optionally substituted with one or more group selected from aryl, heteroaryl, heterocyclo,  $OR_5$ ,  $OC(=O)R_1$ ,  $NR_6R_7$ ,  $NR_5$ ,  $N(C=O)R_5$ ,  $NH(C=O)OR_5$ ,  $NHSO_2R_5$ ,  $NHSO_2NR_5$ , aryl, heteroaryl, heterocyclo, wherein aryl or heteroaryl is optionally substituted with one or more halo, OH,  $CF_3$ , CN,  $NO_2$ ,  $(C_1-C_8)alkyl$ ,  $(C_3-C_6)cycloalkyl$ ,  $S(C_1-C_4)alkyl$ ,  $C(=O)R_1$ ,  $OR_5$ ,  $OC(=O)R_1$ ,  $NR_6R_7$ ,  $NHR_5$ ,  $N(C=O)R_5$ ,  $NH(C=O)OR_5$ ,  $NHSO_2R_5$ ,  $NHSO_2NR_5$ ;

15

J, K, Q independently are  $CR_2$  or N, with the proviso that when any one of J, K, or Q is N, then the other two are  $CR_2$ ;

X, Y, Z independently are  $C=C-R_5$ ,  $O=C$ ,

20

$CH_2$ ,  
 $CHR_3$ ,  
 $CHR_4$ ,  
 $CR_3R_4$ ,  
 $CH(OR_5)$ , or

CHNR<sub>6</sub>R<sub>7</sub>;

R<sub>1</sub> is H,

- 5 (C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
O—(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
10 NH<sub>2</sub>,  
NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>, or  
NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

15 R<sub>2</sub> is H,

- halo,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
O—(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
20 O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
NH<sub>2</sub>,  
NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
25 N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>, or  
NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;

R<sub>3</sub> and R<sub>4</sub> independently are halo,

- 30 (C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
O—(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

5 S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
NH<sub>2</sub>,  
NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>,  
NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;  
aryl,  
(CH<sub>2</sub>)<sub>n</sub>-aryl,  
heterocyclo,  
10 (CH<sub>2</sub>)<sub>n</sub>-heterocyclo,  
heteroaryl, or  
(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;  
wherein n is 0, 1, 2, or 3;

15 R<sub>5</sub> is H,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
aryl,  
(CH<sub>2</sub>)<sub>n</sub>-aryl,  
20 heterocyclo,  
(CH<sub>2</sub>)<sub>n</sub>-heterocyclo,  
heteroaryl, or  
(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;  
wherein n is as defined above;


25 R<sub>6</sub> and R<sub>7</sub> independently are H,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
aryl,  
30 (CH<sub>2</sub>)<sub>n</sub>-aryl,  
heterocyclo,  
(CH<sub>2</sub>)<sub>n</sub>-heterocyclo,

heteroaryl, or


(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;

wherein n is 0, 1, 2, or 3; or R<sub>6</sub> and R<sub>7</sub> together can form a 5-7-membered ring containing 1, 2, or 3 heteroatoms which are N or S.

5




3. The compound of claim 1 as designated in formula IA.




IA

4. The compound of claim 1 as designated in formula IB.






IB


5. The compound of claim 1 as designated in formula IC.







IC

6. The compound of claim 5, wherein P is








7. The compound of claim 6, wherein P is




wherein  $J_a$  is N or  $CR_{10}$ , wherein  $R_{10}$  is H or F, and wherein “~~~~~” indicates the point of attachment.

8. The compound of claim 7, wherein P is






wherein “” indicates the point of attachment; and wherein

R<sub>8</sub> and R<sub>9</sub> are each independently H; halo, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, O—(C<sub>1</sub>-C<sub>4</sub>) alkyl, S—(C<sub>1</sub>-C<sub>4</sub>) alkyl, aryl, (CH<sub>2</sub>)<sub>n</sub>-aryl, heterocyclo, (CH<sub>2</sub>)<sub>n</sub>-heterocyclo, heteroaryl, or (CH<sub>2</sub>)<sub>n</sub>-heteroaryl; wherein n is 0, 1, 2, or 3; or taken together R<sub>8</sub> and R<sub>9</sub> are bonded to the same C and form C=O.

9. A compound of formula II



## II

or a pharmaceutically acceptable salt thereof wherein

A is O,

NH, or

**S;**

**B** is

$$\text{C}(=\text{O})\text{R}_1,$$
$$\text{C}(=\text{S})\text{R}_1,$$

heterocylco,  
heteroaryl,  
C(=O)-heterocyclo, or  
C(=O)-heteteroaryl;

5

D is N when E is C and F is CH when "-----" is a bond, or D is CH when E is N and F is CH<sub>2</sub> when "-----" is absent;



10 is 5-membered heterocyclo or heteroaryl, wherein  
"~~~~~" indicates points of attachment, and wherein the 5-membered heterocyclo or heteroaryl is optionally substituted with one or more group selected from aryl, heteroaryl, heterocyclo, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NR<sub>5</sub>, N(C=O)R<sub>5</sub>, NH(C=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>, aryl, heteroaryl, heterocyclo, wherein aryl or heteroaryl is optionally substituted with one  
15 or more halo, OH, CF<sub>3</sub>, CN, NO<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S(C<sub>1</sub>-C<sub>4</sub>)alkyl, C(=O)R<sub>1</sub>, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NHR<sub>5</sub>, N(C=O)R<sub>5</sub>, NH(C=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>;

20 J, K, Q independently are CR<sub>2</sub> or N, with the proviso that when any one of J, K, or Q is N, then the other two are CR<sub>2</sub>;

X, Y, Z independently are C=C - R<sub>5</sub>, O=C,  
CH<sub>2</sub>,  
CHR<sub>3</sub>,  
25 CHR<sub>4</sub>,  
CR<sub>3</sub>R<sub>4</sub>,  
CH(OR<sub>5</sub>), or  
CHNR<sub>6</sub>R<sub>7</sub>;

30 R<sub>1</sub> is H,

(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
O—(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
5 S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
NH<sub>2</sub>,  
NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>, or  
10 NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

R<sub>2</sub> is H,

halo,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
15 (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
O—(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
20 NH<sub>2</sub>,  
NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>, or  
NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;

25 R<sub>3</sub> and R<sub>4</sub> independently are H, halo,


(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
O—(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
30 S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
NH<sub>2</sub>,

NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>,  
NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;  
aryl,  
5 (CH<sub>2</sub>)<sub>n</sub>-aryl,  
heterocyclo,  
(CH<sub>2</sub>)<sub>n</sub>-heterocyclo,  
heteroaryl, or  
(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;  
10 wherein n is 0, 1, 2, or 3;

R<sub>5</sub> is H,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
15 aryl,  
(CH<sub>2</sub>)<sub>n</sub>-aryl,  
heterocyclo,  
(CH<sub>2</sub>)<sub>n</sub>-heterocyclo,  
heteroaryl, or  
20 (CH<sub>2</sub>)<sub>n</sub>-heteroaryl;  
wherein n is 0, 1, 2, or 3;


R<sub>6</sub> and R<sub>7</sub> independently are H;  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
25 (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
aryl,  
(CH<sub>2</sub>)<sub>n</sub>-aryl,  
heterocyclo,  
(CH<sub>2</sub>)<sub>n</sub>-heterocyclo,  
30 heteroaryl, or  
(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;

wherein n is 0, 1, 2, or 3; or R<sub>6</sub> and R<sub>7</sub> together can form a 5-7-membered ring containing 1, 2, or 3 heteroatoms which are N or S.

10. The compound of claim 9, wherein  is as defined in claim 2.


5

11. The compound of claim 9 as designated in formula IIA.




IIA

- 10 12. The compound of claim 9 as designated in formula IIB.



IIB


13. The compound of claim 9 as designated in formula IIC.



IIC

15

14. The compound of claim 9 as designated in formula IID




IID

wherein  $J_a$  is N or  $CR_{10}$ , wherein  $R_{10}$  is H or F.

5


15. The compound of claim 9 as designated in formula IIE



IIE

- 10 wherein  $R_8$  and  $R_9$  are each independently H; halo,  $(C_1-C_8)$ alkyl,  $(C_3-C_6)$ cycloalkyl,  $O-(C_1-C_4)$  alkyl,  $S-(C_1-C_4)$  alkyl, aryl,  $(CH_2)_n$ -aryl, heterocyclo,  $(CH_2)_n$ -heterocyclo, heteroaryl, or  $(CH_2)_n$ -heteroaryl, wherein n is 0, 1, 2, or 3; or taken together  $R_8$  and  $R_9$  are bonded to the same C and form  $C=O$ .

- 15 16. A compound of formula III



III

or a pharmaceutically acceptable salt thereof wherein:

A is O,  
NH, or  
S;

5 B is  
C(=O)R<sub>1</sub>,  
C(=S)R<sub>1</sub>,  
heterocylco,  
heteroaryl,  
10 C(=O)-heterocyclo, or  
C(=O)-heteteroaryl;

D is N when E is C and F is CH when “-----” is a bond, or D is  
CH when E is N and F is CH<sub>2</sub> when “-----” is absent;

15



is 5-membered heterocyclo or heteroaryl, wherein  
“~~~~~” indicates points of attachment, and wherein the 5-membered  
heterocyclo or heteroaryl is optionally substituted with one or more group  
selected from aryl, heteroaryl, heterocyclo, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NR<sub>5</sub>,  
20 N(C=O)R<sub>5</sub>, NH(C=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>, aryl, heteroaryl,  
heterocyclo, wherein aryl or heteroaryl is optionally substituted with one  
or more halo, OH, CF<sub>3</sub>, CN, NO<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S(C<sub>1</sub>-  
C<sub>4</sub>)alkyl, C(=O)R<sub>1</sub>, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NHR<sub>5</sub>, N(C=O)R<sub>5</sub>,  
NH(C=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>;

25

J, K, Q independently are CR<sub>2</sub> or N, with the proviso that when any  
one of J, K, or Q is N, then the other two are CR<sub>2</sub>;

30 X, Y, Z independently are C=C - R<sub>5</sub>, O=C,  
CH<sub>2</sub>,


5  
CHR<sub>3</sub>,  
CHR<sub>4</sub>,  
CR<sub>3</sub>R<sub>4</sub>,  
CH(OR<sub>5</sub>), or  
CHNR<sub>6</sub>R<sub>7</sub>;

10  
R<sub>1</sub> is H,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
O—(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
15 NH<sub>2</sub>,  
NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>, or  
NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,


20 R<sub>2</sub> is H,  
halo,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
O—(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
25 S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
NH<sub>2</sub>,  
NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>, or  
30 NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;

R<sub>3</sub> and R<sub>4</sub> independently are halo,

- 5                    aryl,  
                        $(CH_2)_n$ -aryl,  
                       heterocyclo,  
                        $(CH_2)_n$ -heterocyclo,  
                       heteroaryl, or  
                        $(CH_2)_n$ -heteroaryl;  
                       wherein n is 0, 1, 2, or 3; or  $R_6$  and  $R_7$  together can form a 5-7-membered  
                       ring containing 1, 2, or 3 heteroatoms which are N or S.


- 10    17.    The compound of claim 16, wherein  is as defined in claim 2.

18.    The compound of claim 16 as designated in formula IIIA.



IIIA

- 15    19.    The compound of claim 16 as designated in formula IIIB.




IIIB

- 20    20.    The compound of claim 16 as designated in formula IIIC.

5 (C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
O—(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
NH<sub>2</sub>,  
NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>,  
10 NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;  
aryl,  
(CH<sub>2</sub>)<sub>n</sub>-aryl,  
heterocyclo,  
(CH<sub>2</sub>)<sub>n</sub>-heterocyclo,  
15 heteroaryl, or  
(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;  
wherein n is 0, 1, 2, or 3;


R<sub>5</sub> is H,  
20 (C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
aryl,  
(CH<sub>2</sub>)<sub>n</sub>-aryl,  
heterocyclo,  
25 (CH<sub>2</sub>)<sub>n</sub>-heterocyclo,  
heteroaryl, or  
(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;  
wherein n is 0, 1, 2, or 3;

30 R<sub>6</sub> and R<sub>7</sub> independently are H,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,



IIC


21. The compound of claim 16 as designated in formula IIID



IIID

wherein  $J_a$  is N or  $CR_{10}$ , wherein  $R_{10}$  is H or F.


22. The compound of claim 16 as designated in formula IIIE



IIIE

- wherein  $R_8$  and  $R_9$  are each independently H; halo,  $(C_1-C_8)$ alkyl,  $(C_3-C_6)$ cycloalkyl,  $O-(C_1-C_4)$  alkyl,  $S-(C_1-C_4)$  alkyl, aryl,  $(CH_2)_n$ -aryl, heterocyclo,  $(CH_2)_n$ -heterocyclo, heteroaryl, or  $(CH_2)_n$ -heteroaryl, wherein  $n$  is 0, 1, 2, or 3; or taken together  $R_8$  and  $R_9$  are bonded to the same C and form  $C=O$ .

23. A compound of formula IV:



IV

or a pharmaceutically acceptable salt thereof wherein:

5

A is O,

NH, or

S;

B is

10

C(=O)R<sub>1</sub>,

C(=S)R<sub>1</sub>,

heterocylco,

heteroaryl,

C(=O)-heterocyclo, or

15

C(=O)-heteteteroaryl;

D is N when E is C and F is CH when “-----” is a bond, or D is CH when E is N and F is CH<sub>2</sub> when “-----” is absent;



20

is 5-membered heterocyclo or heteroaryl, wherein

“~~~~~” indicates points of attachment, and wherein the 5-membered heterocyclo or heteroaryl is optionally substituted with one or more group selected from aryl, heteroaryl, heterocyclo, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NR<sub>5</sub>, N(C=O)R<sub>5</sub>, NH(C=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>, aryl, heteroaryl, heterocyclo, wherein aryl or heteroaryl is optionally substituted with one or more halo, OH, CF<sub>3</sub>, CN, NO<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S(C<sub>1</sub>-

25

C<sub>4</sub>)alkyl, C(=O)R<sub>1</sub>, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NHR<sub>5</sub>, N(C=O)R<sub>5</sub>,  
NH(C=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>;

5 J, K, Q independently are CR<sub>2</sub> or N, with the proviso that when any  
one of J, K, or Q is N, then the other two are CR<sub>2</sub>;

X, Y, Z independently are C=C-R<sub>5</sub>, O=C,  
CH<sub>2</sub>,  
CHR<sub>3</sub>,  
10 CHR<sub>4</sub>,  
CR<sub>3</sub>R<sub>4</sub>,  
CH(OR<sub>5</sub>), or  
CHNR<sub>6</sub>R<sub>7</sub>;

15 R<sub>1</sub> is H,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
O—(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
20 S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
NH<sub>2</sub>,  
NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>, or  
25 NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

R<sub>2</sub> is H,  
halo,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
30 (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
O—(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

5 S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
NH<sub>2</sub>,  
NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>, or  
NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;

10 R<sub>3</sub> and R<sub>4</sub> independently are halo,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
O—(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
15 NH<sub>2</sub>,  
NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>,  
NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;  
aryl,  
20 (CH<sub>2</sub>)<sub>n</sub>-aryl,  
heterocyclo,  
(CH<sub>2</sub>)<sub>n</sub>-heterocyclo,  
heteroaryl, or  
(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;  
25 wherein n is 0, 1, 2, or 3;

30 R<sub>5</sub> is H,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
aryl,  
(CH<sub>2</sub>)<sub>n</sub>-aryl,  
heterocyclo,

(CH<sub>2</sub>)<sub>n</sub>-heterocyclo,  
heteroaryl, or  
(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;  
wherein n is 0, 1, 2, or 3;

5

R<sub>6</sub> and R<sub>7</sub> independently are H,

(C<sub>1</sub>-C<sub>8</sub>)alkyl,

(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

aryl,

10

(CH<sub>2</sub>)<sub>n</sub>-aryl,

heterocyclo,

(CH<sub>2</sub>)<sub>n</sub>-heterocyclo,


heteroaryl, or

(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;

15


wherein n is 0, 1, 2, or 3; or

R<sub>6</sub> and R<sub>7</sub> together can form a 5-7-membered ring containing 1, 2,  
or 3 heteroatoms which are N or S.

24. The compound of claim 23, wherein  is as defined in claim 2.


20

25. The compound of claim 23 as designated in formula IVA.




IVA

25 26. The compound of claim 23 as designated in formula IVB.



IVB


27. The compound of claim 23 as designated in formula IVC.



IVC

5

28. The compound of claim 23 as designated in formula IVD




IVD

10

wherein  $J_a$  is N or  $CR_{10}$ , wherein  $R_{10}$  is H or F. Specific values for K and Q are CH, and CH, respectively.


29. The compound of claim 23 as designated in formula IVE



IVE

wherein  $R_8$  and  $R_9$  are each independently H; halo,  $(C_1-C_8)$ alkyl,  $(C_3-C_6)$ cycloalkyl,  $O-(C_1-C_4)$  alkyl,  $S-(C_1-C_4)$  alkyl, aryl,  $(CH_2)_n$ -aryl, heterocyclo,  $(CH_2)_n$ -heterocyclo, heteroaryl, or  $(CH_2)_n$ -heteroaryl, wherein n is 0, 1, 2, or 3; or taken together  $R_8$  and  $R_9$  are bonded to the same C and form  $C=O$ .

30. A compound of formula V:



V

or a pharmaceutically acceptable salt thereof wherein:

A is O,

NH, or

S;

B is

$C(=O)R_1$ ,

$C(=S)R_1$ ,

heterocylco,

heteroaryl,

$C(=O)$ -heterocyclo, or

C(=O)-heteteroaryl;

D is N when E is C and F is CH when “-----” is a bond, or D is CH when E is N and F is CH<sub>2</sub> when “-----” is absent;

5



is 5-membered heterocyclo or heteroaryl, wherein

“~~~~~” indicates points of attachment, and wherein the 5-membered heterocyclo or heteroaryl is optionally substituted with one or more group selected from aryl, heteroaryl, heterocyclo, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NR<sub>5</sub>, N(C=O)R<sub>5</sub>, NH(C=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>, aryl, heteroaryl, heterocyclo, wherein aryl or heteroaryl is optionally substituted with one or more halo, OH, CF<sub>3</sub>, CN, NO<sub>2</sub>, (C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, S(C<sub>1</sub>-C<sub>4</sub>)alkyl, C(=O)R<sub>1</sub>, OR<sub>5</sub>, OC(=O)R<sub>1</sub>, NR<sub>6</sub>R<sub>7</sub>, NHR<sub>5</sub>, N(C=O)R<sub>5</sub>, NH(C=O)OR<sub>5</sub>, NHSO<sub>2</sub>R<sub>5</sub>, NHSO<sub>2</sub>NR<sub>5</sub>;

10

15

J, K, Q independently are CR<sub>2</sub> or N, with the proviso that when any one of J, K, or Q is N, then the other two are CR<sub>2</sub>;

X, Y, Z independently are C=C-R<sub>5</sub>, O=C,

20

CH<sub>2</sub>,

CHR<sub>3</sub>,

CHR<sub>4</sub>,

CR<sub>3</sub>R<sub>4</sub>,

CH(OR<sub>5</sub>), or

25

CHNR<sub>6</sub>R<sub>7</sub>;

R<sub>1</sub> is H,

(C<sub>1</sub>-C<sub>8</sub>)alkyl,

(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,

30


O-(C<sub>1</sub>-C<sub>4</sub>)alkyl,

O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
NH<sub>2</sub>,  
5 NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>, or  
NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,


R<sub>2</sub> is H,  
10 halo,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
O—(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
15 S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
NH<sub>2</sub>,  
NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>, or  
20 NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;

R<sub>3</sub> and R<sub>4</sub> independently are halo,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
25 O—(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
O—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
S—(C<sub>1</sub>-C<sub>4</sub>) alkyl,  
S—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
NH<sub>2</sub>,  
30 NH(C<sub>1</sub>-C<sub>4</sub>)alkyl,  
N((C<sub>1</sub>-C<sub>4</sub>)alkyl)<sub>2</sub>,  
NH—(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl;

- aryl,  
(CH<sub>2</sub>)<sub>n</sub>-aryl,  
heterocyclo,  
(CH<sub>2</sub>)<sub>n</sub>-heterocyclo,  
5 heteroaryl, or  
(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;  
wherein n is 0, 1, 2, or 3;
- R<sub>5</sub> is H,  
10 (C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
aryl,  
(CH<sub>2</sub>)<sub>n</sub>-aryl,  
heterocyclo,  
15 (CH<sub>2</sub>)<sub>n</sub>-heterocyclo,  
heteroaryl, or  
(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;  
wherein n is 0, 1, 2, or 3;
- 20 R<sub>6</sub> and R<sub>7</sub> independently are H,  
(C<sub>1</sub>-C<sub>8</sub>)alkyl,  
(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
aryl,  
(CH<sub>2</sub>)<sub>n</sub>-aryl,  
25 heterocyclo,  
(CH<sub>2</sub>)<sub>n</sub>-heterocyclo,  
heteroaryl, or  
(CH<sub>2</sub>)<sub>n</sub>-heteroaryl;  
wherein n is 0, 1, 2, or 3; or  
30 R<sub>6</sub> and R<sub>7</sub> together can form a 5-7-membered ring containing 1, 2, or 3  
heteroatoms which are N or S.


31. The compound of claim 30, wherein  is as defined in claim 2.

32. The compound of claim 30 as designated in formula VA.



5 VA


33. The compound of claim 30 as designated in formula VB.



VB


10

34. The compound of claim 30 as designated in formula VC.



VC


- 15 35. The compound of claim 30 as designated in formula VD



VD

wherein  $J_a$  is N or  $CR_{10}$ , wherein  $R_{10}$  is H or F.

- 5 36. The compound of claim 30 as designated in formula VE



VE

- wherein  $R_8$  and  $R_9$  are each independently H; halo,  $(C_1-C_8)$ alkyl,  $(C_3-C_6)$ cycloalkyl,  $O-(C_1-C_4)$  alkyl,  $S-(C_1-C_4)$  alkyl, aryl,  $(CH_2)_n$ -aryl, heterocyclo,  $(CH_2)_n$ -heterocyclo, heteroaryl, or  $(CH_2)_n$ -heteroaryl, wherein n is 0, 1, 2, or 3; or taken together  $R_8$  and  $R_9$  are bonded to the same C and form  $C=O$ .

37. A compound which is:
- 15 (S)-N-[2-Oxo-3-(1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
- 20 (S)-N-[2-Oxo-3-(3-phenyl-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
- (S)-N-{3-[3-(2-Hydroxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 25 (S)-N-{3-[3-(2-Methoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

(S)-N-{2-Oxo-3-[3-(2-trifluoromethoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;

5 (S)-N-{2-Oxo-3-[3-(2-trifluoromethyl-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;

(S)-N-{3-[3-(2-Fluoro-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

10 (S)-N-{3-[3-(3-Hydroxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

(S)-N-{3-[3-(3-Methoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

15 (S)-N-{2-Oxo-3-[3-(3-trifluoromethoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;

20 (S)-N-{2-Oxo-3-[3-(3-trifluormethyl-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;

(S)-N-{3-[3-(3-Fluoro-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

25 (S)-N-{3-[3-(4-Hydroxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

30 (S)-N-{3-[3-(4-Methoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

(S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;

35 (S)-N-{2-Oxo-3-[3-(4-trifluoromethyl-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;

(S)-N-{3-[3-(4-Fluoro-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

40 (S)-N-[2-Oxo-3-(3-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl]-acetamide;

45 (S)-N-{3-[3-(4-Hydroxy-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

- (S)-N-{3-[3-(4-Methoxy-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 5 (S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(4-trifluoromethyl-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 10 (S)-N-{3-[3-(4-Fluoro-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(5-Hydroxy-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 15 (S)-N-{3-[3-(5-Methoxy-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(5-trifluoromethoxy-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 20 (S)-N-{2-Oxo-3-[3-(5-trifluoromethyl-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 25 (S)-N-{3-[3-(5-Fluoro-thiophen-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-[3-(3-Furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 30 (S)-N-{3-[3-(4-Hydroxy-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 35 (S)-N-{3-[3-(4-Methoxy-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 40 (S)-N-{2-Oxo-3-[3-(4-trifluoromethyl-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(4-Fluoro-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 45

- (S)-N-{3-[3-(5-Hydroxy-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 5 (S)-N-{3-[3-(5-Methoxy-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(5-trifluoromethoxy-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 10 (S)-N-{2-Oxo-3-[3-(5-trifluoromethyl-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(5-Fluoro-furan-3-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 15 (S)-N-[2-Oxo-3-(3-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(3-Hydroxy-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 20 (S)-N-{3-[3-(3-Methoxy-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(3-trifluoromethoxy-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 25 (S)-N-{2-Oxo-3-[3-(3-trifluoromethyl-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(3-Fluoro-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 30 (S)-N-{3-[3-(2-Hydroxy-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 35 (S)-N-{3-[3-(2-Methoxy-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(2-trifluoromethoxy-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 40 (S)-N-{2-Oxo-3-[3-(2-trifluoromethyl-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(2-Fluoro-pyridin-4-yl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 45

(S)-N-[3-(5,6-Dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

5 (S)-N-[2-Oxo-3-(3-phenyl-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-{3-[3-(2-Hydroxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

10 (S)-N-{3-[3-(2-Methoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

(S)-N-{2-Oxo-3-[3-(2-trifluoromethoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;

15 (S)-N-{2-Oxo-3-[3-(2-trifluoromethyl-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;

20 (S)-N-{3-[3-(2-Fluoro-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

(S)-N-{3-[3-(3-Hydroxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

25 (S)-N-{3-[3-(3-Methoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

30 (S)-N-{2-Oxo-3-[3-(3-trifluoromethoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;

(S)-N-{2-Oxo-3-[3-(3-trifluoromethyl-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;

35 (S)-N-{2-Oxo-3-[3-(3-trifluoromethyl-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;

(S)-N-{3-[3-(3-Fluoro-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

40 (S)-N-{3-[3-(4-Hydroxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

45 (S)-N-{3-[3-(4-methoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

- (S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 5 (S)-N-{2-Oxo-3-[4-(3-trifluoromethyl-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(4-Fluoro-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 10 (S)-N-[2-Oxo-3-(3-thiophen-3-yl-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
- (S)-N-{3-[3-(4-Hydroxy-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 15 (S)-N-{3-[3-(4-Methoxy-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 20 (S)-N-{2-Oxo-3-[3-(4-trifluoromethyl-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(4-Fluoro-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 25 (S)-N-{3-[3-(5-Hydroxy-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 30 (S)-N-{3-[3-(5-Methoxy-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(5-trifluoromethoxy-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 35 (S)-N-{2-Oxo-3-[3-(5-trifluoromethyl-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 40 (S)-N-{3-[3-(5-Fluoro-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-[3-(3-Furan-3-yl-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;
- 45 (S)-N-{3-[3-(4-Hydroxy-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

- (S)-N-{3-[3-(4-Methoxy-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 5 (S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(4-trifluoromethyl-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 10 (S)-N-{3-[3-(4-Fluoro-thiophen-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(5-Hydroxy-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 15 (S)-N-{3-[3-(5-Methoxy-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(5-trifluoromethoxy-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 20 (S)-N-{2-Oxo-3-[3-(5-trifluoromethyl-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(5-trifluoromethyl-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 25 (S)-N-{3-[3-(5-Fluoro-furan-3-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-[2-Oxo-3-(3-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl]-acetamide;
- 30 (S)-N-{3-[3-(3-Hydroxy-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(3-Methoxy-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 35 (S)-N-{2-Oxo-3-[3-(3-trifluoromethoxy-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 40 (S)-N-{2-Oxo-3-[3-(3-trifluoromethyl-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(3-Fluoro-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 45

- (S)-N-{3-[3-(2-Hydroxy-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 5 (S)-N-{3-[3-(2-Methoxy-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(2-trifluoromethoxy-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 10 (S)-N-{2-Oxo-3-[3-(2-trifluoromethyl-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(2-Fluoro-pyridin-4-yl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-8-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 15 (S)-N-[2-Oxo-3-(1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl)-oxazolidin-5-ylmethyl]-acetamide;
- (S)-N-[2-Oxo-3-(3-phenyl-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl)-oxazolidin-5-ylmethyl]-acetamide;
- 20 (S)-N-{3-[3-(2-Hydroxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(2-Methoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 25 (S)-N-{2-Oxo-3-[3-(2-trifluoromethoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 30 (S)-N-{2-Oxo-3-[3-(2-trifluoromethyl-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(2-Fluoro-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 35 (S)-N-{3-[3-(3-Hydroxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(3-Methoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 40 (S)-N-{2-Oxo-3-[3-(3-trifluoromethoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 45 (S)-N-{2-Oxo-3-[3-(3-trifluoromethyl-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;

- (S)-N-{3-[3-(3-Fluoro-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 5 (S)-N-{3-[3-(4-Hydroxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(4-Methoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 10 (S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(4-trifluoromethyl-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 15 (S)-N-{3-[3-(4-Fluoro-phenyl)-1,4,5,6-tetrahydro-1,2-diaza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 20 (S)-N-[3-(5,6-Dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;
- (S)-N-[2-Oxo-3-(3-phenyl-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl)-oxazolidin-5-ylmethyl]-acetamide;
- 25 (S)-N-{3-[3-(2-Hydroxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(2-Methoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 30 (S)-N-{2-Oxo-3-[3-(2-trifluoromethoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(2-trifluoromethyl-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 35 (S)-N-{3-[3-(2-Fluoro-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 40 (S)-N-{3-[3-(3-Hydroxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(3-Methoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 45

- (S)-N-{2-Oxo-3-[3-(3-trifluoromethoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 5 (S)-N-{2-Oxo-3-[3-(3-trifluoromethyl-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(3-Fluoro-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 10 (S)-N-{3-[3-(4-Hydroxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{3-[3-(4-Methoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- 15 (S)-N-{2-Oxo-3-[3-(4-trifluoromethoxy-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-{2-Oxo-3-[3-(4-trifluoromethyl-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-oxazolidin-5-ylmethyl}-acetamide;
- 20 (S)-N-{3-[3-(4-Fluoro-phenyl)-5,6-dihydro-4H-1-oxa-2-aza-benzo[e]azulen-9-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;
- (S)-N-[3-(2-Methyl-9,10-dihydro-4H-3-thia-1-aza-benzo[f]azulen-7-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;
- 25 (S)-N-[3-(2-Methyl-9,10-dihydro-4H-3-thia-1-aza-benzo[f]azulen-6-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;
- 30 (S)-N-[3-(2-Methyl-5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5ylmethyl] acetamide;
- (S)-N-[3-(2-Amino-5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;
- 35 (S)-N-[3-(2-Methyl-3,4,5,6-tetrahydro-1,3-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;
- 40 (S)-N-[2-Oxo-3-(2-trifluoromethyl-3,4,5,6-tetrahydro-1,3-diaza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
- (S)-N-[2-Oxo-3-(3,4,5,6-tetrahydro-2,3-diaza-benzo[e]azulen-9-yl)-oxazolidin-5-ylmethyl]-acetamide; or
- 45

(S)-N-[3-(5,6-Dihydro-4H-3-oxa-2-aza-benzo[e]azulen-9-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide.

38. A pharmaceutical formulation comprising a compound of claim 1 admixed  
5 with a pharmaceutically acceptable diluent, carrier, or excipient. .

39. A method of treating a bacterial infection in a mammal, comprising  
administering to a mammal in need thereof an effective amount of a compound of  
claim 1.